FENC
FENNEC PHARMACEUTICALS INC.Company Information
- Company Name
- FENNEC PHARMACEUTICALS INC.
- CIK
- CIK0001211583
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- FENC: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- FENC
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-05-19
- Last sale
- 2026-09-15
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 1,360,347
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 16,300,135
- Shares outstanding
- 34,545,000
- Ownership
- 47.19%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 2.74%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 41 | 40 | 37 | 22 | 19 | 23 | 27 | 40 | 43 | 51 | 13 | 12 | ||||||
| Accounts And Other Receivables Net Current | 23 | 19 | 23 | 19 | 18 | 15 | 13 | 13 | 12 | 10 | 9 | 5 | ||||||
| Prepaid Expense Current | 4 | 3 | 4 | 1 | 1 | 2 | 3 | 3 | 4 | 4 | 3 | 0 | ||||||
| Inventory Finished Goods | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | ||||||
| Other Assets Current | 2 | 3 | 2 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 73 | 67 | 67 | 46 | 41 | 43 | 44 | 58 | 62 | 68 | 27 | 19 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Operating Lease Right Of Use Asset | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Accounts Receivable Net Noncurrent | 3 | 4 | 3 | 2 | 3 | 3 | - | - | - | - | - | - | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | ||||||
| Deferred Finance Costs Ownshare Lending Arrangement Issuance Costs Net | - | - | - | - | - | - | - | - | - | - | 1 | 0 | ||||||
| Accumulated Amortization Of Noncurrent Deferred Finance Costs | - | - | - | - | - | - | -2 | - | - | - | -1 | - | ||||||
| Assets Noncurrent | 3 | 5 | 4 | 3 | 4 | 3 | 1 | 1 | 1 | 1 | 0 | 0 | ||||||
| Assets | 76 | 72 | 71 | 49 | 45 | 46 | 45 | 59 | 63 | 69 | 27 | 19 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 6 | 6 | 5 | 6 | 6 | 5 | 3 | 4 | 4 | 5 | 4 | 3 | ||||||
| Accrued Liabilities Current | 4 | 3 | 6 | 4 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 1 | ||||||
| Operating Lease Liability Current | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Contract With Customer Liability Current | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | ||||||
| Liabilities Current | 12 | 10 | 11 | 10 | 8 | 8 | 7 | 7 | 8 | 10 | 8 | 4 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Debt Instrument Carrying Amount | - | - | - | 18 | 18 | 18 | 18 | 30 | 30 | 30 | 30 | 25 | ||||||
| Interest Payable Current And Noncurrent | - | - | - | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | ||||||
| Debt Instrument Unamortized Discount | - | - | - | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Operating Lease Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Contract With Customer Liability Noncurrent | 21 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 0 | - | ||||||
| Liabilities Noncurrent | 21 | 25 | 25 | 44 | 44 | 44 | 44 | 57 | 57 | 56 | 31 | 26 | ||||||
| Liabilities | 33 | 34 | 35 | 54 | 52 | 52 | 51 | 64 | 65 | 66 | 38 | 30 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 193 | 191 | 190 | 148 | 146 | 146 | 146 | 145 | 145 | 145 | 144 | 144 | ||||||
| Additional Paid In Capital Common Stock | 75 | 74 | 74 | 71 | 69 | 68 | 67 | 66 | 64 | 63 | 62 | 61 | ||||||
| Retained Earnings Accumulated Deficit | -227 | -229 | -229 | -225 | -224 | -221 | -220 | -218 | -212 | -206 | -219 | -217 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Stockholders Equity | 42 | 38 | 35 | -4 | -7 | -6 | -6 | -5 | -1 | 3 | -12 | -11 | ||||||
| Liabilities And Stockholders Equity | 76 | 72 | 71 | 49 | 45 | 46 | 45 | 59 | 63 | 69 | 27 | 19 | ||||||
| Common Stock No Par Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Shares Issued | 35 | 35 | 34 | 28 | 28 | 28 | 28 | 27 | 27 | 27 | 27 | 27 | ||||||
| Shares Outstanding | 35 | 35 | 34 | 28 | 28 | 28 | 28 | 27 | 27 | 27 | 27 | 27 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialFENNEC PHARMACEUTICALS INC. (FENC) — SEC Financial Statements & Analysis
FENNEC PHARMACEUTICALS INC. (FENC) is a biological products, (no diagnostic substances) company, incorporated in A1. FENNEC PHARMACEUTICALS INC. trades on Nasdaq as: FENC. FENNEC PHARMACEUTICALS INC. (FENC)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, FENNEC PHARMACEUTICALS INC. carries a market cap of $371.36M, a P/E ratio of -114.26x, a P/B ratio of 8.75x, a P/S ratio of 6.27x, an enterprise value of $330.11M, and an EV/EBITDA multiple of -293.69x. On profitability, it posts a gross margin of 94.08%, an operating margin of -1.90%, a net margin of -5.49%, a Return on Equity (ROE) of -18.58%, and a Return on Assets (ROA) of -5.39%. Per share, it reports EPS of $-0.09, diluted EPS of $-0.09, free cash flow per share of $-0.06, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 77.83% year-over-year, net income growth of -73.00% year-over-year, and EPS growth of -78.38% year-over-year. On the balance sheet, it maintains a current ratio of 5.85x, a quick ratio of 5.36x, working capital of $60.11M, a debt-to-equity ratio of 0.78x, a debt ratio of 0.44, an interest coverage ratio of -1.24x, free cash flow of $-2.04M (TTM), and net debt of $-41.25M. Figures sourced from SEC EDGAR.
- Market Cap
- $371.36M
- P/E TTM
- -114.26x
- EPS TTM
- $-0.09
- P/B TTM
- 8.75x
- ROE TTM
- -18.58%
- ROA TTM
- -5.39%
- Debt To Equity
- 0.78x
- Free Cash Flow TTM
- $-2.04M
- Net Revenue TTM Growth 1Y
- 77.83%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is FENNEC PHARMACEUTICALS INC. in?
FENNEC PHARMACEUTICALS INC. (FENC) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does FENC trade on?
FENNEC PHARMACEUTICALS INC. (FENC) trades on the Nasdaq.
Where is FENNEC PHARMACEUTICALS INC. incorporated?
FENNEC PHARMACEUTICALS INC. is incorporated in British Columbia, Canada.
When was FENNEC PHARMACEUTICALS INC. (FENC)'s most recent SEC filing?
FENNEC PHARMACEUTICALS INC. (FENC)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is FENC's market cap?
FENNEC PHARMACEUTICALS INC. (FENC) has a market capitalization of $371.36M as of 2026-06-30.
What is FENC's EPS (earnings per share)?
FENNEC PHARMACEUTICALS INC. (FENC)'s trailing twelve month EPS is $-0.09 as of 2026-06-30.
What is FENC's ROE (return on equity)?
FENNEC PHARMACEUTICALS INC. (FENC)'s trailing twelve month Return on Equity (ROE) is -18.58% as of 2026-06-30.
What is FENC's ROA (return on assets)?
FENNEC PHARMACEUTICALS INC. (FENC)'s trailing twelve month Return on Assets (ROA) is -5.39% as of 2026-06-30.
What is FENC's EV/EBITDA?
FENNEC PHARMACEUTICALS INC. (FENC)'s trailing twelve month EV/EBITDA is -293.69x as of 2026-06-30.